KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Other Working Capital Changes: 2010-2025

Historic Other Working Capital Changes for Novavax (NVAX) over the last 15 years, with Sep 2025 value amounting to -$11.7 million.

  • Novavax's Other Working Capital Changes fell 131.16% to -$11.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$621.5 million, marking a year-over-year decrease of 339.87%. This contributed to the annual value of -$354.1 million for FY2024, which is 200.92% down from last year.
  • Novavax's Other Working Capital Changes amounted to -$11.7 million in Q3 2025, which was down 140.74% from -$4.9 million recorded in Q2 2025.
  • In the past 5 years, Novavax's Other Working Capital Changes ranged from a high of $549.6 million in Q1 2021 and a low of -$874.6 million during Q4 2022.
  • In the last 3 years, Novavax's Other Working Capital Changes had a median value of -$4.9 million in 2025 and averaged -$56.7 million.
  • As far as peak fluctuations go, Novavax's Other Working Capital Changes soared by 12,256.25% in 2021, and later slumped by 362.67% in 2022.
  • Novavax's Other Working Capital Changes (Quarterly) stood at $333.0 million in 2021, then plummeted by 362.67% to -$874.6 million in 2022, then spiked by 124.23% to $211.9 million in 2023, then tumbled by 100.43% to -$913,000 in 2024, then crashed by 131.16% to -$11.7 million in 2025.
  • Its Other Working Capital Changes was -$11.7 million in Q3 2025, compared to -$4.9 million in Q2 2025 and -$604.0 million in Q1 2025.